Literature DB >> 17329971

Activated PI3K signaling as an endogenous inducer of p53 in human cancer.

Carolyn Lee1, Jung-Sik Kim, Todd Waldman.   

Abstract

Complex pathways exist in mammalian cells to regulate the expression and activity of oncogenes and tumor suppressor genes. Defining these regulatory pathways is an important step towards being able to interfere with tumorigenesis. Here we discuss our recent study indicating that activation of the phosphoinositide 3-kinase (PI3K) signaling pathway through inactivating mutations in PTEN or activating mutations in PIK3CA causes functional activation of p53 signaling in human cells.(1)ur data suggest that activation of p53 is a fail-safe mechanism triggered by loss of PTEN or oncogenic activation of PI3K, and furthermore, that these events provide selective pressure to mutate p53.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329971      PMCID: PMC4394610          DOI: 10.4161/cc.6.4.3810

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  22 in total

1.  Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.

Authors:  Jung-Sik Kim; Carolyn Lee; Challice L Bonifant; Habtom Ressom; Todd Waldman
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

2.  PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms.

Authors:  Daniel J Freeman; Andrew G Li; Gang Wei; Heng-Hong Li; Nathalie Kertesz; Ralf Lesche; Andrew D Whale; Hilda Martinez-Diaz; Nora Rozengurt; Robert D Cardiff; Xuan Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

3.  The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis.

Authors:  J Bar; N Lukaschuk; A Zalcenstein; S Wilder; R Seger; M Oren
Journal:  Cell Death Differ       Date:  2005-06-03       Impact factor: 15.828

4.  Regulation of PTEN transcription by p53.

Authors:  V Stambolic; D MacPherson; D Sas; Y Lin; B Snow; Y Jang; S Benchimol; T W Mak
Journal:  Mol Cell       Date:  2001-08       Impact factor: 17.970

5.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

Review 6.  Perspectives in studies of human tumor viruses.

Authors:  George Klein
Journal:  Front Biosci       Date:  2002-01-01

Review 7.  The role of p53 in tumour suppression: lessons from mouse models.

Authors:  L D Attardi; T Jacks
Journal:  Cell Mol Life Sci       Date:  1999-01       Impact factor: 9.261

8.  The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Authors:  F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

9.  Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway.

Authors:  Hideyuki Miyauchi; Tohru Minamino; Kaoru Tateno; Takeshige Kunieda; Haruhiro Toko; Issei Komuro
Journal:  EMBO J       Date:  2004-01-08       Impact factor: 11.598

10.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

View more
  12 in total

Review 1.  Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.

Authors:  Brian D Lehmann; James A McCubrey; David M Terrian
Journal:  Cancer Biol Ther       Date:  2007-08-05       Impact factor: 4.742

2.  Stepwise-edited, human melanoma models reveal mutations' effect on tumor and microenvironment.

Authors:  Eran Hodis; Elena Torlai Triglia; John Y H Kwon; Tommaso Biancalani; Labib R Zakka; Saurabh Parkar; Jan-Christian Hütter; Lorenzo Buffoni; Toni M Delorey; Devan Phillips; Danielle Dionne; Lan T Nguyen; Denis Schapiro; Zoltan Maliga; Connor A Jacobson; Ayal Hendel; Orit Rozenblatt-Rosen; Martin C Mihm; Levi A Garraway; Aviv Regev
Journal:  Science       Date:  2022-04-29       Impact factor: 63.714

3.  Temporal PTEN inactivation causes proliferation of saphenous vein smooth muscle cells of human CABG conduits.

Authors:  Amit K Mitra; Guanghong Jia; Deepak M Gangahar; Devendra K Agrawal
Journal:  J Cell Mol Med       Date:  2008-03-19       Impact factor: 5.310

Review 4.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

5.  NLK is a novel therapeutic target for PTEN deficient tumour cells.

Authors:  Ana M Mendes-Pereira; Christopher J Lord; Alan Ashworth
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

6.  The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells.

Authors:  Lymor Ringer; Paul Sirajuddin; Lucas Tricoli; Sarah Waye; Muhammad Umer Choudhry; Erika Parasido; Angiela Sivakumar; Mary Heckler; Aisha Naeem; Iman Abdelgawad; Xuefeng Liu; Adam S Feldman; Richard J Lee; Chin-Lee Wu; Venkata Yenugonda; Bhaskar Kallakury; Anatoly Dritschilo; John Lynch; Richard Schlegel; Olga Rodriguez; Richard G Pestell; Maria Laura Avantaggiati; Chris Albanese
Journal:  Oncotarget       Date:  2014-11-15

7.  Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer.

Authors:  Adam Hermawan; Herwandhani Putri; Naufa Hanif; Muthi Ikawati
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-13       Impact factor: 2.629

8.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

Authors:  Ana M Mendes-Pereira; Sarah A Martin; Rachel Brough; Afshan McCarthy; Jessica R Taylor; Jung-Sik Kim; Todd Waldman; Christopher J Lord; Alan Ashworth
Journal:  EMBO Mol Med       Date:  2009-09       Impact factor: 12.137

9.  The Impact of Hyperosmolality on Activation and Differentiation of B Lymphoid Cells.

Authors:  Ljiljana Cvetkovic; Stojan Perisic; Jens Titze; Hans-Martin Jäck; Wolfgang Schuh
Journal:  Front Immunol       Date:  2019-04-18       Impact factor: 7.561

10.  The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.

Authors:  Lei Zhang; Yidong Li; Qianchao Wang; Zhuo Chen; Xiaoyun Li; Zhuoxun Wu; Chaohua Hu; Dan Liao; Wei Zhang; Zhe-Sheng Chen
Journal:  Mol Cancer       Date:  2020-01-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.